This topic contains a solution. Click here to go to the answer

Author Question: A patient has been prescribed a bisphosphonate for treatment of osteoporosis. The nurse prioritizes ... (Read 82 times)

cookcarl

  • Hero Member
  • *****
  • Posts: 539
A patient has been prescribed a bisphosphonate for treatment of osteoporosis. The nurse prioritizes teaching about immediately reporting which finding?
 
  1. New onset thigh pain
  2. Nausea
  3. Headache
  4. Dry, itchy skin

Question 2

Which statements are true regarding opioid receptors?(Select all that apply.)
 
  1. Opioid blockers inhibit both the mu and kappa receptors.
  2. Some opioids stimulate a particular receptor; others block a receptor.
  3. Opioid blockers stimulate both the mu and kappa receptors.
  4. Opioids interact with mu and kappa receptors.
  5. Opioids interact with delta receptors.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

b614102004

  • Sr. Member
  • ****
  • Posts: 320
Answer to Question 1

1
Rationale 1: There is an increased incidence of atypical fractures associated with bisphosphonate use. Thigh or groin pain has been noted to occur prior to fracture.
Rationale 2: Nausea may occur if the patient is on a vitamin D supplement, but this is not the priority.
Rationale 3: Headache may occur if the patient is on a vitamin D supplement, but this is not the priority.
Rationale 4: Skin eruptions are not an effect of bisphosphonate use.

Global Rationale: There is an increased incidence of atypical fractures associated with bisphosphonate use. Thigh or groin pain has been noted to occur prior to fracture. Nausea or headache may occur if the patient is on a vitamin D supplement, but this is not the priority. Skin eruptions are not an effect of bisphosphonate use.

Answer to Question 2

1, 2, 4

Rationale 1: Opioid blockers inhibit both the mu and kappa receptors.
Rationale 2: Some opioids stimulate a particular receptor; others block a receptor.
Rationale 3: Opioid blockers inhibit both the mu and kappa receptors.
Rationale 4: Opioids interact with at least six types of receptors: mu (types one and two), kappa, delta, and nociceptin.
Rationale 5: Opioids interact with at least four types of receptors: mu (types one and two), kappa, delta, and nociceptin.

Global Rationale: Opioid blockers inhibit both the mu and kappa receptors. Some opioids stimulate a particular receptor; others block a receptor. Opioids interact with at least four types of receptors: mu (types one and two), kappa, delta, and nociceptin.




cookcarl

  • Member
  • Posts: 539
Reply 2 on: Jul 23, 2018
Great answer, keep it coming :)


sarah_brady415

  • Member
  • Posts: 328
Reply 3 on: Yesterday
Thanks for the timely response, appreciate it

 

Did you know?

For pediatric patients, intravenous fluids are the most commonly cited products involved in medication errors that are reported to the USP.

Did you know?

Drug abusers experience the following scenario: The pleasure given by their drug (or drugs) of choice is so strong that it is difficult to eradicate even after years of staying away from the substances involved. Certain triggers may cause a drug abuser to relapse. Research shows that long-term drug abuse results in significant changes in brain function that persist long after an individual stops using drugs. It is most important to realize that the same is true of not just illegal substances but alcohol and tobacco as well.

Did you know?

The human body's pharmacokinetics are quite varied. Our hair holds onto drugs longer than our urine, blood, or saliva. For example, alcohol can be detected in the hair for up to 90 days after it was consumed. The same is true for marijuana, cocaine, ecstasy, heroin, methamphetamine, and nicotine.

Did you know?

Normal urine is sterile. It contains fluids, salts, and waste products. It is free of bacteria, viruses, and fungi.

Did you know?

Despite claims by manufacturers, the supplement known as Ginkgo biloba was shown in a study of more than 3,000 participants to be ineffective in reducing development of dementia and Alzheimer’s disease in older people.

For a complete list of videos, visit our video library